Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q9N2B0
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q9N2B0-F1 | Predicted | AlphaFoldDB |
No variants for Q9N2B0
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| No variants for Q9N2B0 | |||||
No associated diseases with Q9N2B0
1 regional properties for Q9N2B0
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | GPCR, rhodopsin-like, 7TM | 44 - 468 | IPR017452 |
1 GO annotations of cellular component
| Name | Definition |
|---|---|
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
1 GO annotations of molecular function
| Name | Definition |
|---|---|
| histamine receptor activity | Combining with histamine to initiate a change in cell activity. Histamine is a physiologically active amine, found in plant and animal tissue and released from mast cells as part of an allergic reaction in humans. |
5 GO annotations of biological process
| Name | Definition |
|---|---|
| cellular response to histamine | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a histamine stimulus. Histamine, the biogenic amine 2-(1H-imidazol-4-yl)ethanamine, is involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter. |
| eosinophil chemotaxis | The movement of an eosinophil in response to an external stimulus. |
| G protein-coupled receptor signaling pathway | The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. |
| positive regulation of vasoconstriction | Any process that activates or increases the frequency, rate or extent of vasoconstriction. |
| regulation of vascular permeability | Any process that modulates the extent to which blood vessels can be pervaded by fluid. |
No homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| No homologous proteins | ||||
| 10 | 20 | 30 | 40 | 50 | 60 |
| MSLPNSSCLL | EDKMCEGNKT | TMASPQLMPL | VVVLSTISLV | TVGLNLLVLY | AVRSERKLHT |
| 70 | 80 | 90 | 100 | 110 | 120 |
| VGNLYIVSLS | VADLIVGAVV | MPMNILYLLM | SKWSLGRPLC | LFWLSMDYVA | STASIFSVFI |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LCIDRYRSVQ | QPLRYLKYRT | KTRASATILG | AWFLSFLWVI | PILGWNHFRQ | QISVRREDKC |
| 190 | 200 | 210 | 220 | 230 | 240 |
| ETDFYDVTWF | KVMTAIINFY | LPTLLMLWFY | AKIYKAVQKH | CQHRELINGS | LPSFSEIKLR |
| 250 | 260 | 270 | 280 | 290 | 300 |
| PENPKGDAKK | PGKESPWEVL | KRKPKDAGGG | SVLKSPSQTP | KEMKSPVVFS | QEDDGEVDKL |
| 310 | 320 | 330 | 340 | 350 | 360 |
| HCFPLDIVQM | QTVAEGSSRD | YVAINQSHGQ | LKTDEQGLNT | HGASEISEDQ | MLGDSQSFSR |
| 370 | 380 | 390 | 400 | 410 | 420 |
| TDSDTTTETA | PGKGKLRSGS | NTGLDYIKFT | WKRLRSHSRQ | YVSGLHMNRE | RKAAKQLGFI |
| 430 | 440 | 450 | 460 | 470 | 480 |
| MAAFILCWIP | YFIFFMVIAF | CKNCCNEHLH | MFTIWLGYIN | STLNPLIYPL | CNENFKKTFK |
| RILHIRS |